Resources from the same session
1488MO - Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)
Presenter: Robin Jones
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1489MO - A phase Ib/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial
Presenter: Cesar Serrano
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1486MO - The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor
Presenter: Hans Gelderblom
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1490MO - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
Presenter: Maria-Veronica Teleanu
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1491MO - New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis
Presenter: Georgios Kantidakis
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1490MO and 1491MO
Presenter: Herbert Ho Fung Loong
Session: Mini Oral session: Sarcoma
Resources:
Slides
Webcast
1487MO - A pan-sarcoma investigation of genetic alterations associated with high telomeric content
Presenter: Radwa Sharaf
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1492MO - Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)
Presenter: Tom Wei-Wu Chen
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1493MO - Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab (neoICB)
Presenter: Elise Nassif
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1487MO, 1492MO and 1493MO
Presenter: Javier Martin-Broto
Session: Mini Oral session: Sarcoma
Resources:
Slides
Webcast